Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

-END-

For more information, please contact: 

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office) Tel: [phone]
Erik Ostrowski / Michelle Avery (US office) [phone]

Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson Tel: [phone]

N+1 Singer 
(Broker)
Aubrey Powell / Lauren Kettle	Tel: [phone]

MacDougall Biomedical Communications
(US media contact) Tel: [phone]
Karen Sharma [e-mail] 

Consilium Strategic Communications
(Financial public relations, UK) Tel: [phone]
Mary-Jane Elliott / Sue Stuart / [e-mail] 
Jessica Hodgson / Lindsey Neville